FOLH1 and prostate carcinoma: In this study we have conjugated a urea-based PSMA-inhibitor to GZMB and PE35 and evaluated the ability of these conjugates to bind and inhibit PSMA, to internalize selectively into PSMA-expressing cells, and to kill prostate cancer cells in vitro and in vivo in a PSMA-specific manner.